Tonix Pharmaceuticals Holding (TNXP) Enterprise Value (2010 - 2026)

Tonix Pharmaceuticals Holding's Enterprise Value history runs 17 years deep, the most recent figure standing at -$155.1 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 17.75% year-over-year to -$155.1 million in Q1 2026; TTM through Mar 2026 was -$155.1 million, a 17.75% decrease from a year earlier, with the FY2025 full-year figure at -$207.6 million, down 108.3% from the prior year.
• Enterprise Value climbed to -$155.1 million in Q1 2026 per TNXP's latest filing, from -$207.6 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$24000.0 in Q2 2024 and bottomed at -$207.6 million in Q4 2025.
• The 5-year median for Enterprise Value is -$99.7 million (2024), against an average of -$88.5 million.
• Across the five-year window, Enterprise Value surged 99.91% in 2024 and tumbled 422816.67% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$120.5 million in 2022, then jumped by 78.54% to -$25.8 million in 2023, then plunged by 285.62% to -$99.7 million in 2024, then sank by 108.3% to -$207.6 million in 2025, then climbed by 25.3% to -$155.1 million in 2026.
• Per Business Quant, the three latest TNXP Enterprise Value figures stand at -$155.1 million (Q1 2026), -$207.6 million (Q4 2025), and -$97.6 million (Q3 2025).